{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:42Z","timestamp":1787960202761,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10557-018-6802-1","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T05:14:35Z","timestamp":1528434875000},"page":"255-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)"],"prefix":"10.1007","volume":"32","author":[{"given":"Marian","family":"Goicoechea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad Garc\u00eda","family":"de Vinuesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bernis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fern\u00e1ndez-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"de Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Verdalles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Lu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"issue":"2","key":"6802_CR1","first-page":"179","volume":"34","author":"J Miner","year":"2007","unstructured":"Miner J, Hoffhines A. The discovery of aspirin\u2019s antithrombotic effects. Tex Heart Inst J. 2007;34(2):179\u201386.","journal-title":"Tex Heart Inst J"},{"key":"6802_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2017.04.005","volume":"189","author":"F Violi","year":"2017","unstructured":"Violi F, Targher G, Vestri A, Carnevale R, Averna M, Farcomeni A, et al. Background effect of aspirin on renal disease progression in patients with type 2 diabetes: a multicenter, double-blind, placebo-controlled, randomized trial. The renaL disease progression by aspirin in diabetic patients (LEDA) trial. Rationale and study design. Am Heart J. 2017;189:120\u20137.","journal-title":"Am Heart J"},{"key":"6802_CR3","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038\u201347.","journal-title":"JAMA"},{"key":"6802_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","volume":"91","author":"RO Mathew","year":"2017","unstructured":"Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91:797\u2013807.","journal-title":"Kidney Int"},{"key":"6802_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201360.","journal-title":"Lancet"},{"key":"6802_CR6","unstructured":"US Food and Drug Administration. Information for consumers (drugs): use of aspirin for primary prevention of heart attack and stroke. Available at: https:\/\/ \n                    www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/ucm390574.htm\n                    \n                  . Accessed 17 Mar 2017."},{"key":"6802_CR7","doi-asserted-by":"crossref","unstructured":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):836\u201345.","DOI":"10.7326\/M16-0577"},{"key":"6802_CR8","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","volume":"70","author":"D Charytan","year":"2006","unstructured":"Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021\u201330.","journal-title":"Kidney Int"},{"key":"6802_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","volume":"156","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156:445\u201359.","journal-title":"Ann Intern Med"},{"issue":"3","key":"6802_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s11886-015-0566-z","volume":"17","author":"D Desai","year":"2015","unstructured":"Desai D, Ahmed HM, Michos ED. Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention. Curr Cardiol Rep. 2015;17(3):566.","journal-title":"Curr Cardiol Rep"},{"key":"6802_CR11","first-page":"94","volume":"316","author":"AL Weigert","year":"1998","unstructured":"Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sc. 1998;316:94\u2013104.","journal-title":"Am J Med Sc"},{"issue":"5","key":"6802_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ahj.2003.11.009","volume":"147","author":"T Lenderink","year":"2004","unstructured":"Lenderink T, Boersma E, Ruzyllo W, GUSTO IV-ACS Investigators, et al. Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. Am Heart J. 2004;147(5):865\u201373.","journal-title":"Am Heart J"},{"issue":"12","key":"6802_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.7326\/M15-2113","volume":"164","author":"JM Guirguis-Blake","year":"2016","unstructured":"Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):804\u201313.","journal-title":"Ann Intern Med"},{"issue":"3","key":"6802_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.nefro.2016.10.002","volume":"37","author":"S Cede\u00f1o Mora","year":"2017","unstructured":"Cede\u00f1o Mora S, Goicoechea M, Torres E, Verdalles \u00da, P\u00e9rez de Jos\u00e9 A, Verde E, et al. Cardiovascular risk prediction in chronic kidney disease patients. Nefrologia. 2017;37(3):293\u2013300.","journal-title":"Nefrologia"},{"issue":"6618","key":"6802_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313\u20136.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"3","key":"6802_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group. Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N Engl J Med. 1989;321(3):129\u201335.","journal-title":"N Engl J Med"},{"issue":"8","key":"6802_CR17","doi-asserted-by":"publisher","first-page":"e104179","DOI":"10.1371\/journal.pone.0104179","volume":"9","author":"AJ Kim","year":"2014","unstructured":"Kim AJ, Lim HJ, Ro H, Ko KP, Han SY, Chang JH, et al. Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease. PLoS One. 2014;9(8):e104179. Published online 2014 Aug 5","journal-title":"PLoS One"},{"issue":"12","key":"6802_CR18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","volume":"56","author":"MJ Jardine","year":"2010","unstructured":"Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"6802_CR19","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","volume":"368","author":"WH Tang","year":"2013","unstructured":"Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575\u201384.","journal-title":"N Engl J Med"},{"issue":"1","key":"6802_CR20","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.2001.281.1.F1","volume":"281","author":"RC Harris","year":"2001","unstructured":"Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol. 2001;281(1):F1\u201311.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"6802_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0024-3205(99)00603-7","volume":"66","author":"M Okumura","year":"2000","unstructured":"Okumura M, Imanishi M, Yamashita T, Yamamura Y, Kim S, Iwao H, et al. Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes. Life Sci. 2000;66(5):371\u20137.","journal-title":"Life Sci"},{"issue":"9","key":"6802_CR22","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1097\/01.ASN.0000136300.72480.86","volume":"15","author":"JJ Boffa","year":"2004","unstructured":"Boffa JJ, Just A, Coffman TM, Arendshorst WJ. Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice. J Am Soc Nephrol. 2004;15(9):2358\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"6802_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000070172","volume":"68","author":"M Lomnicka","year":"2003","unstructured":"Lomnicka M, Karouni K, Sue M, Wessel LA, Bing RJ. Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane in the kidney. Pharmacology. 2003;68(3):147\u201353.","journal-title":"Pharmacology"},{"issue":"9","key":"6802_CR24","first-page":"2358","volume":"15","author":"JJ Boffa","year":"2004","unstructured":"Boffa JJ, Just A, Coffman TM, et al. Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice. J Am Soc. 2004;15(9):2358\u201365.","journal-title":"J Am Soc"},{"key":"6802_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","volume":"45","author":"C Baigent","year":"2005","unstructured":"Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"6802_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0272-6386(03)00647-4","volume":"42","author":"T Kurth","year":"2003","unstructured":"Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, Stampfer MJ, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42(2):234\u201344.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6802_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/SLA.0000000000000641","volume":"261","author":"L Yao","year":"2015","unstructured":"Yao L, Young N, Liu H, Li Z, Sun W, Goldhammer J, et al. Evidence for preoperative aspirin improving major outcomes in patients with chronic kidney disease undergoing cardiac surgery: a cohort study. Ann Surg. 2015;261(1):207\u201312.","journal-title":"Ann Surg"},{"key":"6802_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ijcard.2016.08.224","volume":"223","author":"D Pastori","year":"2016","unstructured":"Pastori D, Pignatelli P, Perticone F, Sciacqua A, Carnevale R, Farcomeni A, et al. Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. Int J Cardiol. 2016;223:619\u201324.","journal-title":"Int J Cardiol"},{"issue":"6","key":"6802_CR29","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","volume":"24","author":"M Evans","year":"2009","unstructured":"Evans M, Fored CM, Bellocco R, Fitzmaurice G, Fryzek JP, McLaughlin JK, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009;24(6):1908\u201318.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"6802_CR30","doi-asserted-by":"publisher","first-page":"e0147635","DOI":"10.1371\/journal.pone.0147635","volume":"11","author":"S Okada","year":"2016","unstructured":"Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al. Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 Cohort Study. PLoS One. 2016;11(1):e0147635.","journal-title":"PLoS One"},{"key":"6802_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.ajkd.2007.07.007","volume":"50","author":"J Ethier","year":"2007","unstructured":"Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50:602\u201311.","journal-title":"Am J Kidney Dis"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6802-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T23:20:26Z","timestamp":1559949626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6802-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["6802"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6802-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"8 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}